CRISPR Therapeutics
CRSP
381 hedge funds and large institutions have $2.54B invested in CRISPR Therapeutics in 2023 Q1 according to their latest regulatory filings, with 48 funds opening new positions, 103 increasing their positions, 120 reducing their positions, and 58 closing their positions.
11% more call options, than puts
Call options by funds: $79.7M | Put options by funds: $71.8M
3% more capital invested
Capital invested by funds: $2.46B → $2.54B (+$84.6M)
0.57% more ownership
Funds ownership: 70.92% → 71.49% (+0.57%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
4% less funds holding
Funds holding: 398 → 381 (-17)
14% less repeat investments, than reductions
Existing positions increased: 103 | Existing positions reduced: 120
17% less first-time investments, than exits
New positions opened: 48 | Existing positions closed: 58
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$32.6M |
| 2 |
Capital International Investors
Los Angeles,
California
|
+$32.5M |
| 3 |
Millennium Management
New York
|
+$10.6M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$10.4M |
| 5 |
Two Sigma Investments
New York
|
+$8.47M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$14.2M |
| 2 |
Goldman Sachs
New York
|
-$12.6M |
| 3 |
PI
PEAK6 Investments
Chicago,
Illinois
|
-$10.8M |
| 4 |
AC
Armistice Capital
New York
|
-$10.3M |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$9.89M |
CRSP Hedge Fund Activity: Q1 2023 in Review
381 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in CRISPR Therapeutics (CRSP) for Q1 2023, worth a combined $2.54B — up 3.4% from $2.46B a quarter earlier.
Sellers outnumbered buyers: 58 funds closed out of CRSP and 48 opened new positions — a net loss of 10 holders — while 120 trimmed existing stakes and 103 added.
The largest buyer was T. Rowe Price Investment Management, adding an estimated $32.6M. The largest seller was Renaissance Technologies, cutting an estimated $14.2M.
- 381 institutional investors held CRISPR Therapeutics (CRSP) as of Q1 2023, down from 398 in Q4 2022.
- Funds reported $2.54B of CRISPR Therapeutics stock for Q1 2023, up 3.4% quarter-over-quarter.
- 48 funds opened new CRISPR Therapeutics positions in Q1 2023 and 58 closed out, a net change of -10 holders.
- The largest CRISPR Therapeutics buyer in Q1 2023 was T. Rowe Price Investment Management, an estimated $32.6M added.
- The largest CRISPR Therapeutics seller in Q1 2023 was Renaissance Technologies, an estimated $14.2M sold.
Based on aggregated 13F filings for Q1 2023.